Age-Friendly Health Systems 4M Training For Healthcare Practitioners

Module 3: Mentation and Medication

Presenters: Isabel Rovira, MPH Raymond Ownby, MD, PhD, MBA Todd James, MD



Dr. Kiran C. Patel College of Osteopathic Medicine NOVA SOUTHEASTERN UNIVERSITY Florida

South Florida Geriatric Workforce Enhancement Program

Age-Friendly Health Systems 4M Training For Healthcare Practitioners

Series Objectives

By the end of the training, participants will be able to:

- 1. Understand the need for Age-Friendly Health Systems (AFHS)
- 2. Communicate the AFHS 4'M model
- 3. Identify your scope, role, and opportunities to practice the 4Ms in the healthcare setting

Schedule

Age-Friendly Health Systems 4M Training For Healthcare Practitioners

Module 1: Introduction to Age-Friendly Health Systems

• Thursday, June 3, 2021 • 10:00 am EST

Module 2: Deep Dives – What Matters Most & Mobility

• Thursday, June 10, 2021 • 10:00 am EST




Module 3: Deep Dives – Mentation & Medication

• Thursday, June 17, 2021 • 10:00 am EST

Module 4: Putting it All Together

• Thursday, June 24, 2021 • 10:00 am EST

Module 3 : Mentation and Medication June 17th, 2021



Agenda

Age-Friendly Health Systems 4M Training For Healthcare Practitioners

Module 3: Mentation and Medication

Welcome & Introduction Isabel Rovira, MPH

Mentation Raymond Ownby, MD, PhD, MBA

> Medication Todd James, MD

> > Q & A

Mentation

Raymond Ownby, MD, PhD, MBA

Professor and Chair, Department of Psychiatry and Behavioral Medicine, Professor, Public Health and Biomedical Informatics Programs Nova Southeastern University



South Florida Geriatric Workforce Education Program

Dementia Prevention and Brain Health: Mentation

Ray Ownby, MD, PhD

4M Training for Healthcare Practitioners June 17, 2021

Dr. Kiran C. Patel College of Osteopathic Medicine NOVA SOUTHEASTERN UNIVERSITY Florida

South Florida Geriatric Workforce Education Program

Disclosures



- Grant support:
 - National Institute on Aging
 - National Institute on Minority Health and Health Disparities
- Stock ownership
 - Enalan Communications, Inc.

Learning Objectives



- After this presentation, participants will be able to:
 - List sources of evidence that cognitive decline may be preventable
 - List three modifiable lifestyle factors related to improved brain health
 - State two strategies for encouraging behavior change for brain health.



01IntroductionQuestionWhy "brain health?"Can dementia be
prevented?03Analysis
Modifiable lifestyleConclusion
Recommendations

factors



02

Why brain health?







Fig. 1. Agents in clinical trials for treatment of Alzheimer's disease in 2018 (from clinical trials.gov accessed January 30, 2018).

Treatments



Amyloid

Amyloid-β

Changes in processing this protein are key in the pathology of Alzheimer's disease and related to cognitive function in persons without a clinical diagnosis of dementia.

Reaction to approval

F.D.A. Approves Alzheimer's Drug Despite Fierce Debate Over Whether It Works

Aducanumab, or Aduhelm, is the first new Alzheimer's treatment in 18 years and the first to attack the disease process. But some experts say there's not enough evidence it can address cognitive symptoms.

NEWS 08 June 2021

Landmark Alzheimer's drug approval confounds research community

Many scientists say there is not enough evidence that Biogen's aducanumab is an effective therapy for the disease.

Three F.D.A. Advisers Resign Over Agency's Approval of Alzheimer's Drug

The drug, Aduhelm, a monthly infusion priced at \$56,000 per year, was approved this week despite weak evidence that it helps patients.

Prevention

Preventing Cognitive Decline and Dementia: A Way Forward

Committee on Preventing Dementia and Cognitive Impairment

Alan I. Leshner, Story Landis, Clare Stroud, and Autumn Downey, Editors

Board on Health Sciences Policy

Health and Medicine Division

National Academy of Sciences, June, 2017

Also see: Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimertype dementia. Agency for Health Research and Quality, Comparative Effectiveness Report Number 188, March 2017.

Prevention

Global Health



Nearly Half of Dementia Cases Could Be Prevented or Delayed

parment, smoking, obesity, depression, physical inactivity, diabetes, and low social contact. Since then, the commission has reported that emerging evidence points to 3 more preventable dementia risk factors: head injuries or excessive alcohol consumption in midlife and air pollution exposure in later life.

ance by the end of 2021.

Currently, 75 wealthier countries that would pay upfront for their own doses have expressed interest in joining. Another 90 lower-income countries could participate through a financing mechanism established by Gavi, the Vaccine Alliance, which leads the COVAX Pillar along with the Coalition for Encidence Innova-



risk factors that could prevent or delay dementia.

JAMA. 2020;324(11):1025. doi:10.1001/jama.2020.16210

The Lancet Commissions

Dementia prevention, intervention, and care: 2020 report of @ 💃 🖲 the Lancet Commission

Gill Livingston, Jonathan Huntley, Andrew Sommerlad, David Ames, Clive Ballard, Sube Banerjee, Carol Brayne, Alistair Burns, Jiska Cohen-Mansfield, Claudia Cooper, Serqi G Costafreda, Amit Dias, Nick Fox, Laura N Gitlin, Robert Howard, Helen C Kales, Mika Kivimäki, Eric B Larson, Adesola Ogunniyi, Vasiliki Orgeta, Karen Ritchie, Kenneth Rockwood, Elizabeth L Sampson, Quincy Samus, Lon S Schneider, Geir Selbæk, Linda Teri, Naaheed Mukadam

Executive summary

The number of older people, including those living with dementia, is rising, as younger age mortality declines. However, the age-specific incidence of dementia has fallen in many countries, probably because of improvements in education, nutrition, health care, and lifestyle changes,

against dementia. Using hearing aids appears to reduce the excess risk from hearing loss. Sustained exercise in midlife, and possibly later life, protects from dementia, perhaps through decreasing obesity, diabetes, and cardiovascular risk. Depression might be a risk for dementia, but in later life dementia might cause Huntley PhD A Sommerlad PhI

Published Online July 30, 2020 https://doi.org/10.1016/ \$0140-6736(20)30367-6 **Division of Psychiatry** (Prof G Livingston MD,

www.thelancet.com Published online July 30, 2020 https://doi.org/10.1016/S0140-6736(20)30367-6

Prevention

Prevention

Lancet Commission 2020

Modifying 12 risk factors might prevent or delay up to 40% of dementias:

- Prevent/treat diabetes
- Treat hypertension
- Prevent head injury
- Stop smoking
- Reduce air pollution
- Reduce midlife obesity
- Exercise
- Reduce occurrence of depression
- Avoid excessive alcohol
- Treat hearing impairment
- Social interaction
- Attain high level of education

www.thelancet.com Published online July 30, 2020 https://doi.org/10.1016/S0140-6736(20)30367-6

Prevention

Brain Maintenance

"Brain maintenance" is the primary factor in successful cognitive aging.

Genes and lifestyle are keys.

Interventions can promote brain structure and function with increasing age.

Nyberg et al. (2012) Trends in Cognitive Sciences, 16, 292-305.

Exercise



Meta-analysis of exercise effects on cognition




Figure 1 | Meta-analytic findings of exercise-training effects on cognition in older adults. The

Hillman et al., Nat Rev Neurosci, 2008, 9, 58-65.

Exercise

Exercise

Exercise training increases size of hippocampus and improves memory


Kirk I. Erickson^a, Michelle W. Voss^{b,c}, Ruchika Shaurya Prakash^d, Chandramallika Basak^e, Amanda Szabo^f, Laura Chaddock^{b,c}, Jennifer S. Kim^b, Susie Heo^{b,c}, Heloisa Alves^{b,c}, Siobhan M. White^f, Thomas R. Wojcicki^f, Emily Mailey^f, Victoria J. Vieira^f, Stephen A. Martin^f, Brandt D. Pence^f, Jeffrey A. Woods^f, Edward McAuley^{b,f}, and Arthur F. Kramer^{b,c,1}

^aDepartment of Psychology, University of Pittsburgh, Pittsburgh, PA 15260; ^bBeckman Institute for Advanced Science and Technology, and ^fDepartment of Kinesiology and Community Health, University of Illinois, Champaign-Urbana, IL 61801; ^cDepartment of Psychology, University of Illinois, Champaign-Urbana, IL 61820; ^dDepartment of Psychology, Rice University, Houston, TX 77251

Edited* by Fred Gage, Salk Institute, San Diego, CA, and approved December 30, 2010 (received for review October 23, 2010)

Erickson KI et al. (2011). Proceedings of the National Academy of Sciences, 108, 3017-3022.

Exercise



Erickson KI et al. (2011). Proceedings of the National Academy of Sciences, 108, 3017-3022.



Mediterranean diet


- The Mediterranean diet emphasizes olive oil, fish, cheese and yogurt, as well as fresh fruits and vegetables
- Beans, legumes, and nuts are important
- Whole grain breads and pastas



Diet

Disson, 2015 2.9% 0.64 [0.31, 1.32] Roberts, 2010 7.3% 0.78 [0.51, 1.19] Scarmeas, 2009-MCI 11.0% 0.72 [0.52, 1.00] Subtotal (95% CI) 59.1% 0.83 [0.75, 0.93] Heterogeneity: Tau ² = 0.00; Ch ² = 1.78, df = 4 (P = 0.76), I ² = 0% Feart, 2009 2.4% 0.86 [0.39, 1.90] Morris, 2015 5.1% 0.49 [0.29, 0.83] Disson, 2015 2.3% 0.99 [0.44, 2.23] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% CI) 24.2% 0.60 [0.42, 0.86] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% CI) 24.2% 0.60 [0.48, 0.77] Heterogeneity: Tau ² = 0.00; Chi ² = 3.09, df = 4 (P = 0.54), I ² = 0% Test for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 0.85 [0.44, 1.64] Subtotal (95% CI) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.75), I ² = 0% Total (95% CI) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22% Heterogeneity: Tau ² = 0.0003)		0.82 [0.59, 1.14] 0.64 [0.31, 1.32]		
Haring, 2016 10.8% 0.82 [0.59, 1.14] Olsson, 2015 2.9% 0.64 [0.31, 1.32] Roberts, 2010 7.3% 0.78 [0.51, 1.19] Scarmeas, 2009-MCI 11.0% 0.72 [0.52, 1.00] Teivgoulis, 2013 27.1% 0.87 [0.76, 1.00] Subtotal (95% CI) 59.1% 0.83 [0.75, 0.93] Heterogeneity: Tau ² = 0.00; Chi ² = 1.78, df = 4 ($P = 0.78$), $P = 0\%$ Test for overall effect: $Z = 3.22$ ($P = 0.001$) AD Feart, 2009 2.4% 0.86 [0.39, 1.90] Morris, 2015 5.1% 0.49 [0.29, 0.83] Olsson, 2015 2.3% 0.99 [0.44, 2.23] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% CI) 24.2% 0.60 [0.48, 0.77] Heterogeneity: Tau ² = 0.00; Chi ² = 3.09, df = 4 ($P = 0.54$), $P = 0\%$ Test for overall effect: $Z = 4.18$ ($P < 0.0001$) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 0.85 [d.41, 1.64] Subtotal (95% CI) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.53), df = 2 ($P = 0.75$), $P = 0\%$ Test for overall effect: $Z = 0.48$ ($P = 0.63$) Total (95% CI) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 ($P = 0.22$); $P = 22\%$		0.64 [0.31, 1.32]	10.8%	MCI
Disson, 2015 2.9% 0.64 [0.31, 1.32] Roberts, 2010 7.3% 0.78 [0.51, 1.19] Scarmeas, 2009-MCI 11.0% 0.72 [0.52, 1.00] Subtotal (95% CI) 59.1% 0.83 [0.75, 0.93] Heterogeneity: Tau ² = 0.00; Ch ² = 1.78, df = 4 (P = 0.76); l ² = 0% Fest for overall effect: Z = 3.22 (P = 0.001) AD Feart, 2009 2.4% 0.86 [0.39, 1.90] Morris, 2015 5.1% 0.49 [0.29, 0.83] Disson, 2015 2.3% 0.99 [0.44, 2.23] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% CI) 24.2% 0.60 [0.42, 0.86] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% CI) 24.2% 0.60 [0.48, 0.77] Heterogeneity: Tau ² = 0.00; Ch ² = 3.09, df = 4 (P = 0.54); l ² = 0% Fest for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Disson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% CI) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Ch ² = 0.58, df = 2 (P = 0.75); l ² = 0% Fest for overall effect: Z = 0.48 (P = 0.63) Fotal (95% CI) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Ch ² = 15.38, df = 12 (P = 0.22); l ² = 22% Heterogeneity: Tau ² = 0.003		0.64 [0.31, 1.32]		
Roberts, 2010 7.3% 0.78 [0.51, 1.19] Scarmeas, 2009-MCI 11.0% 0.72 [0.52, 1.00] Tsiygoulis, 2013 27.1% 0.87 [0.76, 1.00] Subtotal (95% CI) 59.1% 0.83 [0.76, 0.09] Heterogeneity: Tau ² = 0.00; Chi ² = 1.78, df = 4 (P = 0.78); I ² = 0% Feart, 2009 2.4% 0.86 [0.39, 1.90] Morris, 2015 5.1% 0.49 [0.29, 0.83] Olsson, 2015 2.3% 0.99 [0.44, 2.23] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% CI) 24.2% 0.60 [0.42, 0.86] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% CI) 24.2% 0.60 [0.48, 0.77] Heterogeneity: Tau ² = 0.00; Chi ² = 3.09, df = 4 (P = 0.54); I ² = 0% Feart, 2009 Fest for overall effect: Z = 4.18 (P < 0.0001)				
Scarmeas, 2009-MCI 11.0% 0.72 $[0.52, 1.00]$ Fsivgoulis, 2013 27.1% 0.87 $[0.76, 1.00]$ Subtotal (95% CI) 59.1% 0.83 $[0.75, 0.93]$ Heterogeneity: Tau ² = 0.00; Ch ² = 1.78, df = 4 (P = 0.76), P = 0% Test for overall effect: Z = 3.22 (P = 0.001) AD Feart, 2009 2.4% 0.86 $[0.39, 1.90]$ Morris, 2015 5.1% 0.49 $[0.29, 0.83]$ Olsson, 2015 2.3% 0.99 $[0.44, 2.23]$ Scarmeas, 2009-AD 4.7% 0.52 $[0.30, 0.90]$ Scarmeas, 2009-AD 4.7% 0.60 $[0.42, 0.86]$ Scarmeas, 2009-AD 4.7% 0.60 $[0.42, 0.86]$ Scarmeas, 2009-AD 4.7% 0.60 $[0.48, 0.77]$ Heterogeneity: Tau ² = 0.00; Ch ² = 3.09, df = 4 (P = 0.54), P = 0% Test for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 $[0.60, 2.09]$ Haring, 2016 9.6% 1.13 $[0.79, 1.62]$ Olsson, 2015 3.4% 0.85 $[0.44, 1.64]$ Subtotal (95% CI) 16.7% 1.07 $[0.81, 1.42]$ Heterogeneity: Tau ² = 0.00; Ch ² = 0.53) Total (95% CI) 100.0% 0.79 $[0.70, 0.90]$ Heterogeneity: Tau ² = 0.01; Ch ² = 15.38, df = 12 (P = 0.22); P = 22% Fest for overall effect: Z = 0.48 (P = 15.38, df = 12 (P = 0.22); P = 22%				
Tsivgoulis, 2013 27.1% 0.87 [0.76, 1.00] Subtotal (95% CI) 59.1% 0.83 [0.75, 0.93] Heterogeneity: Tau ² = 0.00; Chi ² = 1.78, df = 4 (P = 0.78); P = 0% Test for overall effect: Z = 3.22 (P = 0.001) AD Feart, 2009 2.4% 0.86 [0.39, 1.90] Morris, 2015 5.1% 0.49 [0.29, 0.83] Olsson, 2015 2.3% 0.99 [0.44, 2.23] Scarmeas, 2009-AD 4.7% 0.60 [0.42, 0.86] Scarmeas, 2009-AD 4.7% 0.60 [0.42, 0.86] Scarmeas, 2009-AD 4.7% 0.60 [0.48, 0.77] Heterogeneity: Tau ² = 0.00; Chi ² = 3.09, df = 4 (P = 0.54); P = 0% Test for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Olsson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% CI) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.75); P = 0% Test for overall effect: Z = 0.48 (P = 0.63) Total (95% CI) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); P = 22%				
Subtotal (95% CI) 59.1% 0.83 $[0.75, 0.93]$ Heterogeneity: Tau ² = 0.00; Ch ² = 1.78, df = 4 (P = 0.78); I ² = 0% Fest for overall effect: Z = 3.22 (P = 0.001) AD Feart, 2009 2.4% 0.86 $[0.39, 1.90]$ Morris, 2015 5.1% 0.49 $[0.29, 0.83]$ Disson, 2015 2.3% 0.99 $[0.44, 2.23]$ Scarmeas, 2009-AD 4.7% 0.52 $[0.30, 0.90]$ Subtotal (95% CI) 24.2% 0.60 $[0.48, 0.77]$ Heterogeneity: Tau ² = 0.00; Ch ² = 3.09, df = 4 (P = 0.54); I ² = 0% Fest for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 $[0.60, 2.09]$ Haring, 2016 9.6% 1.13 $[0.79, 1.62]$ Disson, 2015 3.4% 0.85 $[0.44, 1.64]$ Subtotal (95% CI) 16.7% 1.07 $[0.81, 1.42]$ Heterogeneity: Tau ² = 0.00; Ch ² = 0.58, df = 2 (P = 0.75); I ² = 0% Fest for overall effect: Z = 0.48 (P = 0.63) Fotal (95% CI) 100.0% 0.79 $[0.70, 0.90]$ Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22%				
Heterogeneity: Tau ² = 0.00; Ch ² = 1.78, df = 4 (P = 0.78); P = 0% Test for overall effect: Z = 3.22 (P = 0.001) AD Fear, 2009 2.4% 0.86 [0.39, 1.90] Morris, 2015 5.1% 0.49 [0.29, 0.83] Disson, 2015 2.3% 0.99 [0.44, 2.23] Scarmeas, 2006 9.6% 0.60 [0.42, 0.86] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% Cl) 24.2% 0.60 [0.48, 0.77] Heterogeneity: Tau ² = 0.00; Ch ² = 3.09, df = 4 (P = 0.54); P = 0% Test for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Disson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% Cl) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Ch ² = 0.58, df = 2 (P = 0.76); P = 0% Test for overall effect: Z = 0.48 (P = 0.63) Total (95% Cl) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Ch ² = 15.38, df = 12 (P = 0.22); P = 22%				
Test for overall effect: $Z = 3.22$ (P = 0.001) AD Feart, 2009 2.4% 0.86 [0.39, 1.90] Morris, 2015 5.1% 0.49 [0.29, 0.83] Olsson, 2015 2.3% 0.99 [0.44, 2.23] Scarmeas, 2006 9.6% 0.60 [0.42, 0.86] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% CI) 24.2% 0.60 [0.48, 0.77] Helerogeneity: Tau ² = 0.00; Chi ² = 3.09, df = 4 (P = 0.54); I ² = 0% Test for overall effect: $Z = 4.18$ (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Olsson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% CI) 16.7% 1.07 [0.81, 1.42] Helerogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.75); I ² = 0% Test for overall effect: $Z = 0.48$ (P = 0.63) Total (95% CI) 100.0% 0.79 [0.70, 0.90] Helerogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22% Test for overall effect: $Z = 3.63$ (P = 0.0003)				
Feart, 2009 2.4% 0.86 [0.39, 1.90] thorris, 2015 5.1% 0.49 [0.29, 0.83] Disson, 2015 2.3% 0.99 [0.44, 2.23] Scarmeas, 2006 9.6% 0.68 [0.42, 0.86] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% CI) 24.2% 0.60 [0.48, 0.77] telerogeneity: Tau ² = 0.00; Chi ² = 3.09, df = 4 (P = 0.54); I ² = 0% Fest for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] taring, 2016 9.6% 1.13 [0.79, 1.62] Disson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% CI) 16.7% 1.07 [0.81, 1.42] telerogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.75); I ² = 0% Fest for overall effect: Z = 0.48 (P = 0.63) Fotal (95% CI) 100.0% 0.79 [0.70, 0.90] telerogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22% Test for overall effect: Z = 3.63 (P = 0.0003)				
Feart, 2009 2.4% 0.86 [0.39, 1.90] Morris, 2015 5.1% 0.49 [0.29, 0.83] Disson, 2015 2.3% 0.99 [0.44, 2.23] Scarmeas, 2006 9.6% 0.60 [0.42, 0.86] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% CI) 24.2% 0.60 [0.48, 0.77] Heterogeneity: Tau ² = 0.00; Ch ² = 3.09, df = 4 (P = 0.54); P = 0% Fest for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Disson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% CI) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Ch ² = 0.58, df = 2 (P = 0.75); P = 0% Test for overall effect: Z = 0.48 (P = 16.38, df = 12 (P = 0.22); P = 22% Fest for overall effect: Z = 3.63 (P = 0.0003)				AD
Morris, 2015 5.1% 0.49 [0.29, 0.83] Olsson, 2015 2.3% 0.99 [0.44, 2.23] Scarmeas, 2006 9.6% 0.60 [0.42, 0.86] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% Cl) 24.2% 0.60 [0.48, 0.77] Heterogeneity: Tau ² = 0.00; Chi ² = 3.09, df = 4 (P = 0.54); I ² = 0% Test for overall effect: Z = 4.18 (P < 0.0001) Dementia Freart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Olsson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% Cl) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.75); I ² = 0% Test for overall effect: Z = 0.48 (P = 0.63) Total (95% Cl) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22%		0.86 (0.39, 1.90)	2 4%	
Olsson, 2015 2.3% 0.99 $[0.44, 2.23]$ Scarmeas, 2006 0.8% 0.60 $[0.42, 0.86]$ Scarmeas, 2009-AD 4.7% 0.52 $[0.30, 0.90]$ Subtotal (95% CI) 24.2% 0.60 $[0.48, 0.77]$ Heterogeneity: Tau ² = 0.00; Chi ² = 3.09, df = 4 (P = 0.54), I ² = 0% Test for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 $[0.60, 2.09]$ Haring, 2016 9.6% 1.13 $[0.79, 1.62]$ Olsson, 2015 3.4% 0.85 $[0.44, 1.64]$ Subtotal (95% CI) 16.7% 1.07 $[0.81, 1.42]$ Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.76), I ² = 0% Test for overall effect: Z = 0.48 (P = 0.63) Total (95% CI) 100.0% 0.79 $[0.70, 0.90]$ Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22%	* *			
Scarmeas, 2006 9.6% 0.60 [0.42, 0.86] Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Scarmeas, 2009-AD 24.2% 0.60 [0.48, 0.77] Heterogeneity: Tau ² = 0.00; Chi ² = 3.09, df = 4 (P = 0.54), P = 0% Test for overall effect Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Olsson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% Cl) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.75); P = 0% Test for overall effect Z = 0.48 (P = 0.63) Total (95% Cl) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); P = 22% Heterogeneity: Tau ² = 3.63 (P = 0.0003)	•			
Scarmeas, 2009-AD 4.7% 0.52 [0.30, 0.90] Subtotal (95% CI) 24.2% 0.60 [0.48, 0.77] Heterogeneity: Tau ² = 0.00; Ch ² = 3.09, df = 4 (P = 0.54); P = 0% Fest for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Disson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% CI) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Ch ² = 0.58, df = 2 (P = 0.75); P = 0% Fest for overall effect: Z = 0.48 (P = 0.63) Total (95% CI) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Ch ² = 15.38, df = 12 (P = 0.22); P = 22% Fest for overall effect: Z = 3.63 (P = 0.0003)	•			
Subtotal (95% CI) 24.2% 0.60 [0.48, 0.77] Heterogeneity: Tau ² = 0.00; Chi ² = 3.09, df = 4 (P = 0.54); l ² = 0% Test for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Olsson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% CI) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.75); l ² = 0% Test for overall effect: Z = 0.48 (P = 0.63) Total (95% CI) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); l ² = 22%	◆ 			
Heterogeneity: Tau ² = 0.00; Chi ² = 3.09, df = 4 (P = 0.54); P = 0% Test for overall effect: Z = 4.18 (P < 0.0001) Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Olsson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% Cl) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.76); I ² = 0% Test for overall effect: Z = 0.48 (P = 0.63) Total (95% Cl) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22%				
Test for overall effect: $Z = 4.18 (P < 0.0001)$ Dementia Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Olsson, 2015 3.4% 0.85 [0.44, 1.64] Olsson, 2015 0.68, df = 10 (P = 0.76); P = 0% Test for overall effect: $Z = 0.48 (P = 0.63)$ Total (95% CI) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); P = 22% Test for overall effect: $Z = 3.63 (P = 0.0003)$				
Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Olsson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% Cl) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.75); I ² = 0% Total (95% Cl) Total (95% Cl) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22% 1001 Test for overall effect: Z = 3.63 (P = 0.0003) 1001				
Feart, 2009 3.8% 1.12 [0.60, 2.09] Haring, 2016 9.6% 1.13 [0.79, 1.62] Olsson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% CI) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.75); I ² = 0% Test for overall effect: Z = 0.48 (P = 0.63) Total (95% CI) 100.0% 0.79 [0.70, 0.90]				Dementia
Haring, 2016 9.6% 1.13 [0.79, 1.62] Olsson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% CI) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.68, df = 2 (P = 0.75); I ² = 0% Test for overall effect: Z = 0.48 (P = 0.63) Total (95% CI) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22% Test for overall effect: Z = 3.63 (P = 0.0003)		1 1 2 10 60 2 091	3.8%	
Olsson, 2015 3.4% 0.85 [0.44, 1.64] Subtotal (95% Cl) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 ($P = 0.75$); $P = 0\%$ Test for overall effect: Z = 0.48 ($P = 0.63$) Total (95% Cl) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 ($P = 0.22$); $P = 22\%$				
Subtotal (95% Cl) 16.7% 1.07 [0.81, 1.42] Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.75); I ² = 0% Total (95% Cl) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22%				
Heterogeneity: Tau ² = 0.00; Chi ² = 0.58, df = 2 (P = 0.75); P = 0% Test for overall effect: Z = 0.48 (P = 0.63) Total (95% Cl) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); P = 22% Test for overall effect: Z = 3.63 (P = 0.0003)	•			
Test for overall effect: Z = 0.48 (P = 0.63) Total (95% CI) 100.0% 0.79 [0.70, 0.90] Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22% ↓ Test for overall effect: Z = 3.63 (P = 0.0003) ↓	ſ			
Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22%				
Heterogeneity: Tau ² = 0.01; Chi ² = 15.38, df = 12 (P = 0.22); I ² = 22%	•	0.79 [0.70, 0.90]	100.0%	Total (95% CI)
Test for overall effect: Z = 3.63 (P = 0.0003)	04			
	⁷⁰ 0.01 01 1 10 100			
	0.0%			
reacter subareas amerenases. Off = 0.34. ar = 2 ar = 0.0017.1 = 13.370	0.070	5.54. di = 2 di = 0.0017.1 = 75		reactor suburous dillere

Wu, L. Sun, D. (2017). Adherence to Mediterranean diet and risk of developing cognitive disorders: An updated systematic review and meta-analysis of prospective cohort studies. *Scientific Reports*, 7, 41317. doi: 10.1038/srep41317 (2017).





Sleep

Poor sleep linked to increased dementia risk

Semin Neurol. 2017 Aug; 37(4): 395-406


Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels.

Brain. 2017 Aug; 140(8): 2104–2111

Slow wave sleep is a promising intervention target for Alzheimer's Disease

Front. Neurosci., 30 June 2020 https://doi.org/10.3389/fnins.2020.00705

CSF Brain fluid flow switches direction in deep sleep



Søren Grubb, and Martin Lauritzen Science 2019;366:572-573

Science MAAAS

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works



Cognitive Training

Life moves pretty fast. If you don't stop and look around once in awhile, you could miss it.

> --Ferris Bueller



Cognitive Training

- Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) study
- Began in 1996
- Six sites
- 2,832 participants
- National Institute on Aging
- Four groups: (1) memory, (2) reasoning, (3) speed of processing, and (4) control
- 10 sessions over 6 weeks
- Intervention for speed of processing
 - Useful Field of View




Figure redrawn from Rebok et al (2014). Journal of the American Geriatrics Society, 62, 16-24.

Risk of Developing Dementia

Cognitive Training

Treatment


Risk:

- 331 participants developed dementia:
 - Control: 14%
 - 10 or fewer sessions: 12.1%
 - 11 to 14 sessions: 8.2%
- Speed training associated with lower risk for dementia by 8% per session
- HR, 0.52; CI 0.33 0.82; *P* = .005

What about combining treatments?



Combined physical/cognitive training in aged MCI subjects: the Train the Brain study



Train the Brain Consortium, Nature Sci Rep, 2017, 7: 39741.

Multicomponent interventions may interact with apo E and amyloid




FIGURE 3 Evidence supporting the efficacy of multidomain interventions on cognitive performance in genetically and molecularly defined subgroups of participants at increased risk for dementia. Values are differences between the mean changes in intervention versus control groups (after 1 year in 1109 participants to the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability [FINGER].²⁰ and after 3 years in 72 participants to the Multidomain Alzheimer Preventive Trial [MAPT]²³ study). A positive value reflects a greater effect of the experimental intervention, whereas a negative value of the control intervention (see also Table 1). The effect of intervention was significant in FINGER apolipoprotein E (APOE) =4 carriers and MAPT amyloid-positive participants, but not in FINGER APOE =4 non-carriers nor MAPT amyloid-negative participants. The interaction of intervention by APOE =4 carrier status in FINGER was not statistically significant, while amyloid positivity in MAPT was significant. Bars represent 95% confidence intervals. NTB: neuropschological test battery

Frisoni et al. Alzheimer's Dement. 2020;16:1457–1468.

Multicomponent interventions and ADLs

Study name	Statistics for each study					Hedges's g and 95% Cl				
	Hedges's g	Lower limit	Upper limit	p-Value						
Barreto et al. (2017)	0.179	-0.229	0.588	0.390	1	1	-	1		
Burge et al. (2016)_Trial 1	0.186	-0.123	0.495	0.238						
Burge et al. (2016)_Trial 2	0.156	-0.153	0.465	0.323						
Rolland et al. (2007)_Trial 1	0.367	0.027	0.706	0.034						
Rolland et al. (2007)_Trial 2	0.660	0.314	1.006	0.000						
Vreugdenhil et al. (2012)_Trial 1	0.527	-0.092	1.145	0.095						
Vreugdenhil et al. (2012)_Trial 2	0.232	-0.378	0.841	0.456						
	0.313	0.163	0.463	0.000			•			
					-4.00	-2.00	0.00	2.00	4.00	

Flávia Borges-Machado, MSc, Nádia Silva, PhD, Paulo Farinatti, PhD, Roberto Poton, PhD, Óscar Ribeiro, PhD, Joana Carvalho, PhD, Effectiveness of Multicomponent Exercise Interventions in Older Adults With Dementia: A Meta-Analysis, *The Gerontologist*, 2020;, gnaa091, <u>https://doi.org/10.1093/geront/gnaa091</u>.

Putting it together



Brain health training program

Daily

Aerobic exercise

Mentally stimulating activities

Meditation

Mediterranean diet

Sleep

Brain health training program

Weekly

Cognitive training at least 3 times/week Strength training at least 3 times/week

Encouraging behavior change

- Motivational interviewing
 - Empathy
 - Develop discrepancy
 - Acknowledge resistance change
 - Support self-efficacy

Encouraging behavior change

- Facilitate goal "SMART" goal setting
 - Specific
 - Measurable
 - Achievable
 - Relevant
 - Time specific

Bottom line



Cognitive Aging and Dementia Prevention Dementia prevention is possible through promoting brain health.

Cognitive Aging and Dementia Prevention Dementia prevention is possible through promoting brain health.

Specific types of cognitive training, exercise and diet may slow cognitive aging and reduce dementia incidence. Cognitive Aging and Dementia Prevention Dementia prevention is possible through promoting brain health.

Specific types of cognitive training, exercise and diet may slow cognitive aging and reduce dementia incidence.

A brain health plan should be part of a comprehensive strategy for senior health.

Brain Health Study– enrolling now

All procedures are online

ClinicalTrials.gov Identifier: NCT04822129

Want to Stay Sharp as You Get Older?

- Are you 50 or older?
- Are you interested in brain health?
- Do you want to learn more about diet, exercise, and mental training as a way to stay sharp as you get older?

If your answers to these questions are yes, you may be eligible to participate in a research study at Nova Southeastern University.

If you are in this study, you will be paid for your time.

We want to find out more about ways to help people develop brain health programs that can help them stay sharp as they get older. If you are in this study, you will receive access to online cognitive assessments and cognitive training, and participate in weekly meetings with Dr. Ownby about brain health, cognitive training, and ways to stay sharp as you get older. To be in the study, you have to have a computer or tablet, an e-mail address, and an internet connection so that you can do the study online.

This study is being done by Dr. Ray Ownby at Nova Southeastern University at the Center for Collaborative Research, 3301 South University Drive, Ft. Lauderdale.

For more information, call Rosemary Davenport, MSN, ARNP at 954-262-1804 or Dr. Ownby at 954-262-1481.



Brain health study (enrolling now)

Inclusion

50 years of age or older

Interest in brain health

Interest in learning more about how to develop a personal brain health program

Have a computer or tablet with internet connection and an e-mail address

Brain health study (enrolling now)

Intervention

12 week study

Weekly video conferences

Cognitive assessment and free access to a commercial cognitive training site

Participants will be compensated for their time

Comparing treatment as usual with intensive behavior change support

Cogtrastim study (enrolling now) Contacts Rosemary Davenport, ARNP 954-262-1804 bap2@bellsouth.net Ray Ownby, MD, PhD 954-262-1481 ro71@nova.edu

www.sfbrainhealth.com



Choosing Wisely for Older Patients

Opportunities to Address Age Friendly Care: Medications

Todd James, MD, AGSF, FACP Associate Professor of Medicine UCSF Division of Geriatrics



June 17, 2021

Disclosures

No Disclosures

Background

THE UNIVERSITY OF ILLINOIS COLLEGE OF MEDICINE CHICAGO PEORIA ROCKFORD URBANA

- Geriatrics Consult Services
- Age-Friendly Emergency Department







Age-Friendly 4M's



For mixed work, this graphic may be used to its entirely actival sequesting permission Graphic blas and guidance at th anyokgeFrendty

What Matters

Know and align care with each older adult's specific health outcome goals and care preferences including, but not limited to, end-of-life care, and across settings of care.

Medication

If medication is necessary, use Age-Friendly medication that does not interfere with What Matters to the older adult, Mobility, or Mentation across settings of care.

Mentation

Prevent, identify, treat, and manage dementia, depression, and delirium across settings of care.

Mobility


Ensure that older adults move safely every day in order to maintain function and do What Matters.

Objectives

- To describe resources for identifying Potentially Inappropriate Medications
- To illustrate risks in specific clinical scenarios for older adults
- To describe evidence which alters management for common practices
- To formulate improved care plans engaging interprofessional resources

Goal: Appropriate Medications

- Cure Disease
- Prevent Disease Progression
- Improve Symptoms
- Improve Functioning





How can we identify PIMs* PIMs* = Potentially Inappropriate Medications

- Choosing Wisely
- AGS Beers Criteria for PIMs
- Screening Tool for Older People's Prescriptions (STOPP)
- European Union (EU)(7)-PIM list

Hill-Taylor B, Walsh KA, Stewart S, Hayden J, Byrne S, Sketris IS. Effectiveness of the STOPP/START (Screening Tool of Older Persons' potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016 Apr;41(2):158-69.

Paul Gallagher, Denis O'Mahony, STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria, *Age and Ageing*, Volume 37, Issue 6, November 2008, Pages 673–679, <u>https://doi.org/10.1093/ageing/afn197</u>

A POCKET GUIDE TO THE 2019 AGS BEERS CRITERIA®

Triprolidine

0

PIMs = Potentially Inappropriate Medications

Organ System, Therapeutic Category, Drug(s)	Recommendation, Rationale, Quality of Evidence (QE), Strength of Recommendation (SR)			
Anticholinergics *				
First-generation antihistamines: Brompheniramine Carbinoxamine Chlorpheniramine Clemastine Cyproheptadine Dexbrompheniramine Dexchlorpheniramine Dimenhydrinate Dimenhydrinate Diphenhydramine (oral) Doxylamine Hydroxyzine Meclizine Promethazine Pyrilamine	Avoid Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity Use of diphenhydramine in situations such as acute treatment of severe allergic reaction may be appropriate <i>QE = Moderate; SR = Strong</i>			

STOPP Criteria

Example

STOPP

Bladder antimuscarinic drugs

- with dementia
 - o risk of increased confusion, agitation
- with chronic glaucoma
 - risk of acute exacerbation of glaucoma
- with chronic constipation
 - o risk of exacerbation of constipation
- with chronic prostatism
 - o risk of urinary retention

PIMs = Potentially Inappropriate Medications

IHI lists these PIMs as Big Offenders

- Benzodiazepines
- Opioids
- Highly-anticholinergic medications
- All prescription and over-thecounter sedatives and sleep medications
- Muscle relaxants
- Tricyclic antidepressants
- Antipsychotics

Review High-Risk Medications

- Engage the older adult and caregiver in review.
- Medicare beneficiaries may be eligible for an annual comprehensive medication review.
- Medication reconciliation, part of the Medicare Annual Wellness Visit.

ABIM Asks What may be Wiser? Choosing Wisely Program

- Specialty societies asked to identify practices that providers should question
- Care supported by evidence
- Care that is free from harm
- Care that is necessary

American Geriatrics Society

- AGS submitted 10 practices
- Practices reviewed today reference Medication Cascade Antipsychotics Benzodiazepines



Leading Change. Improving Care for Older Adults.



Patient Stories



Dee Prescribee



Dee fills her own pill boxes, 18 pills/day. Her daughter sees errors in pill box.

Medications added to treat side effects of other medications

Increased risks of:

- Receiving incorrect medications
- Adverse drug reactions
- Nonadherence



Adverse drug reactions include:

- Cognitive impairment
- Falls
- Functional decline



Steinman MA, Hanlon JT. JAMA. 2010;304(14):1592-1601.

• 40% of older adults take ≥5 prescriptions
 [3x more than 20 years ago]

• Add OTC's and 20% of older adults ≥10 agents

Boyd CM, et al. JAMA. 2005;294(6):716-724. Steinman MA. Am J Geriatr Pharmacother. 2007;5(4):314-316. Brownlee, et al. Health Affairs Blog, May 20, 2019

Medication Review Helps identify:

- Unnecessary medications
- Potentially harmful medications
- Underuse of medications

• Opportunities to reduce medication burden

Drenth-van Maanen AC. Drugs Aging. 2009;26(8):687-701.


Context of Medication Review Matters

- Goals of care
- Life expectancy
- Time to benefit
- Burden of therapy
- Values/quality of life that are preferred? --see Preferences Tool

van Summeren JJ, et al. Outcome prioritisation tool for medication review in older patients with multimorbidity: a pilot study in general practice. Br J Gen Pract. 2017 Jul;67(660):e501-e506.


Reuben DB. Medical Care for the Final Years of Life "When You're 83, It's Not Going to Be 20 Years" *JAMA*. 2009;302(24):2686-2694.

Preferences Tool




Fried TR, Tinetti M, Agostini J, Iannone L, Towle V. Health outcome prioritization to elicit preferences of older persons with multiple health conditions. Patient Educ Couns. 2011 May;83(2):278-82.

Patient Priorities Care



Patient Priorities Care aligns care among all clinicians with what matters most to their patients. It recognizes that patients are the experts in what they want to achieve from their healthcare, while clinicians are the experts in how to get them there.

Deprescribing Canada



Deprescribing Network



Resources for Clinicians

The US Deprescribing Research Network is focused on research. We encourage clinicians looking for clinical information and resources relevant to deprescribing to peruse the excellent content prepared by partner colleagues and organizations. Please note that this is not a comprehensive list.

Guidelines on Deprescribing Common Medications

Evidence-based, easy-to-use algorithms for deprescribing commonly used medications. Includes the algorithms, full guidelines, and whiteboard videos, prepared by the Bruyere Research Institute and University of Montreal.

- Deprescribing Guidelines and Algorithms
- Deprescribing Algorithms
- Educational Videos For Clinicians

Deprescribing guidance for common medications from the governments of New South Wales and Tasmania, Australia



of Older Americans Harmed by Too Many Medications

Lown Institute just released Eliminating Medication Overload: A National Action Plan. more

medication overload, press release

Eliminating Medication Overload



LOW-VALUE CARE

Medication overload and older Americans



Medication Cascade

- Case resolution: Dee Prescribee visits primary care team with her daughter.
- Daughter is concerned and brings large brown bag of all the bottles she can find.
- Goals discussed, time-to-benefit and values reviewed.
- Decision to prioritize vascular meds; work from med-list only; trial reduction to 7 pills



This Photo by Unknown Author is licensed under CC BY-SA

• Advice: Don't use antipsychotics as first choice to treat behavioral and psychological symptoms of dementia.




This Photo by Unknown Author is licensed under <u>CC BY-NC-ND</u>

• Case Study: Andy, an 89 yo man with moderately advanced dementia; he lives at home; his wife Mary watches him 24/7; he disassembles furniture, he has episodes at which he energetically attempts to leave the house; he's aggressive; Mary's friend's husband got daily Haldol for his behaviors. Mary wants to try Haldol. His last doctor gave them lorazepam.



- Mary would like a break. Can't we calm Andy?
- All dementias may exhibit behaviors: agitation, apathy, repetitive questioning, aggression, wandering, sleep problems, inappropriate behaviors, resistance to care.
- Have you seen these?

- Antipsychotics are often prescribed
- Yet, provide little benefit and can cause harm
- What is efficacy of antipsychotics?



- No efficacy for behaviors. Sedation.
- Worsening cognitive function,

lower urinary tract symptoms

- Increased risk of death, stroke, extrapyramidal symptoms (NNH=10 for olanzapine)
- Off-label

Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. J JAMA. 2011 Sep 28;306(12):1359-69. doi: 10.1001/jama.2011.1360. Review. Erratum in: JAMA. 2012 Jan 11;307(2):147. PubMed PMID: 21954480.

Gill SS, Bronskill SE, Normand SL, Anderson GM, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007 Jun 5;146(11):775-86. PubMed PMID: 17548409.

Vigen, Mack, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011 Aug;168(8):831-9. doi: 10.1176/appi.ajp.2011.08121844. Epub 2011 May 15. PubMed PMID: 21572163; PubMed Central PMCID: PMC3310182.

- For Andy he's at baseline
- What is diagnosis? Need history and evaluation.
- What other dx & drugs may be adding symptoms: anticholinergics (TylenolPM), sedatives, narcotics, hypnotics
- Seems like: Behavioral and psychological symptoms of dementia.

Behavioral and psychological symptoms of dementia

Common problems (of most concern to caregivers)
Repetitive questioning
Argumentativeness
Toileting issues
Upset, agitated, restless
Refusing care
Awake at night
Verbal aggression
Wandering

Behavioral and psychological symptoms of dementia

Common problems (of most concern to caregivers)	Solutions
Repetitive questioning	Expect to provide repetitive answers. Re-orient.
Argumentativeness	Agree. Model behavior. Avoid debating.
Toileting issues	Timed voiding.
Upset, agitated, restless	Daytime activity and structure. Provide pet? Be calm.
Refusing care	Be flexible. Relax rules so long as safe.
Awake at night	Establish routines. Hire overnight coverage. Avoid bedtime beverages and caffeine.
Verbal aggression	Distract. Redirect. Identify and avoid antecedents.
Wandering	Daytime exercise and activity. Safety-proof walkways.

DICE Addresses Undesirable Behaviors

• Describe, Investigate, Create, and Evaluate (DICE), created by a national multidisciplinary panel of experts in dementia care, based on the current evidence as well as clinical experience.

Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015 Mar 2;350:h369. doi: 10.1136/bmj.h369. Review. PubMed PMID: 25731881; PubMed Central PMCID: PMC4707529.

DICE model for behavioral problems in dementia

- Describe situations where problem behaviors occur
- Investigate problems that might combine with these factors and lead to behavioral issues
- Create a plan to prevent/respond to behavioral issues
- Evaluate how the plan is working and change it if needed

Guiding the Caregiver in Managing the Behavioral Symptoms of Dementia

amazon	Books *								Q	0 - A
Select your address	Today's Deals	Best Sellers	rind a GML Cust	omer Service	New Releases	Registry	Gift Cards	Sell Amazor	Basics	÷
Books Advanced Search New colas - Health, Fitness & Dieting + N		i Sellers & Mare	Children's Books (*		New Year No New Year No n great re	ne You	r 2020	Best Books of th + <u>Shop no</u>	24	
	Er.	Sympto	E Approad ms of Dem (also MC (Author) 5 million	entia Pap	erback - Jan	uary 4, 20	019			oral
Status in Lington of Several A	 See all fo Paperback S28.90 See from 5 	627.26								
		evidence-in The creator	ally renowned an formed method to of The DICE A y or facility care	for assessin pproach ¹⁴ h	g and managing ove written an e	g the behav any-to-und	rioral symp	toms of deman	stia.	



There are an estimated 16 million informal (family or friend) caregivers of people living with dementia in the US and those numbers will increase rapidly as beby boomers age. While dementia is often thought of < Read more

- Case resolution
- For support, wife asks family members to schedule themselves for supervision and activity shifts on a calendar. They found he likes to disassemble Legos and is not bothered by someone assembling Lego blocks. Doors are locked with key locks and keys are kept by his wife. Sign on door that Train Line is on strike.





This Photo by Unknown Author is licensed under CC BY-SA

Advice:

Don't use benzodiazepines or other sedative-hypnotics in older adults as first choice for insomnia, agitation or delirium.



This Photo by Unknown Author is licensed under CC BY-SA

 Case study: Bennie Zapine, an 84 yo woman moved to assisted living and wants to sleep at 9:30PM. Everyone else does! She was an RN and worked 2nd shift; never in adult life went to bed before 1AM. Her husband always sent the kids to school. She wants a prescription!

A common problem

- Chronic sleep problem: 57% of older adults
- Alprazolam and zolpidem among top 20 prescriptions in US
- Used by 12% of community-dwelling elderly, 13% of nursing home residents

Foley *Sleep* 1995. http://www.imshealth.com. Aparasu *J Am Geriatr Soc* 2003. Stevenson *Am J Geriatr Psychiatry* 2010.

Observational data

• Motor vehicle accidents

- 1.6-fold increase (95% CI, 1.29–1.97)
- Crashes requiring hospitalization
 - 5.3-fold increase (95% CI, 3.6–7.9)
 - Comparable to a blood alcohol level at the legal limit

Observational data

Falls leading to hospitalization and death
1.83-fold increase (95% CI, 1.10–3.06)

Stenbacka Alcohol 2002. Finkle J Amer Geriatr Soc 2011.

Observational data



Hip fractures 3.11-fold increase (95% CI, 1.96–4.91) Risk greater with zolpidem

"Wake up refreshed and recharged."

"Patients who take insomnia drugs can experience impairment of mental alertness the morning after use, even if they feel fully awake."

FDA 1/10/13

Randomized trials

 • 24 RCTs, 2,417 participants, mean age ≥60, sedatives for ≥5 nights Adverse Events

• Memory loss, confusion, disorientation

• 4.78-fold increase (95% CI, 1.47–15.5)

Glass, Sedative hypnotics in older people with insomnia: Meta- analysis of risks and benefits. *BMJ* 2005.

Adverse events

• Daytime fatigue

• 3.82-fold increase (95% CI, 1.88–7.80)

• Dizziness, loss of balance, falls

• 2.61-fold increase (95% CI, 1.12–6.09)

Effectiveness in older adults

- Improved sleep quality: 0.11 pts (7-point scale)
 - Increased sleep time: 25 minutes (95% CI, 12.8–37.8)
 - Decreased night-time awakenings: -0.63 (95% CI, -0.48 to -0.77)

Benefits versus harms

• NNT: 13 (95% CI, 6.7–62.9)

• NNH: 6 (95% CI, 4.7–7.1)

• Adverse event more than twice as likely as improved sleep

Glass *BMJ* 2005.

Cognitive-behavioral therapy


• More effective and durable than drug therapy for late-life insomnia

• No adverse effects

Morin JAMA 1999. Sivertsen JAMA 2006.

Two exceptions

- Sedative-hypnotics are useful for:
 - Alcohol withdrawal/delirium tremens
 - Severe generalized anxiety disorder



Home + Steep Science + Incomnia-Curbing Apps Are Beginning To Use Actual Cognitive Therapy

Insomnia-Curbing Apps Are Beginning To Use Actual Cognitive Therapy

Disclosure

Transparency Disclosure - We may receive a referral fee (at no additional cost to the buyer) for products purchased through the links on our site or other applicable pages. To learn more, please read our full disclosure

Sleep Diary Reminder

Art 15, 1976

Jun 29, 3016

6 hours 30 minutes

Winding Down

Schedule Worry Time

	5 17				page have the size approximate course and						
Carolyn Burke	+++ (2)(2) (83)										
	Last Updated Dn August 15, 2019	80									
			٠	Mac	Pad	Phone	Watch	τv	Music	Support	
			App S	tore Previe	9W						Ì
			This app is available only on the App Store for								
				BT-	i	CBT-i Coaci US Department of US Department of Tree	of Veterans A	VMairs (VA)			
		iPhone	Screensho	ts							
			About	CET-iCeach	Settings	Click Quiet Your M		Clack See	ep Diary Help	Cancel	ĺ
					4	Relaxation exercises are op- help your body learn to rela-	s. Thy each of	Part and to Day 1	Dany companion: 117	June 20, 20	
				8 3		the exercises to determine on the most appealing and use		And there is a first of	and succession of	Old your map or	l

My Steep


2

Learn

1000

0

Reminders



Q.

A 1 8 1944

760

- Case resolution for Benny Zapine
- We advised of risks and described our unwillingness to give sedative hypnotic, since harms were more likely than benefit.
- Reviewed prior sleep patterns, sleep hygiene, re-setting with alarm clock every time she came to clinic offer CBT-i coach app

What is Wiser for Medications?

Recognize some practices that we should question
Care that is supported by evidence
Care that is free from harm
Care that is beneficial

Summary

- Medication Cascade: Dee Prescribee
- Antipsychotics: Andy
- Benzodiazepines: Bennie Zapine



Returning to Our Objectives

- We reviewed rationales for identifying Potentially Inappropriate Medications (Beers, STOPP, Choosing Wisely initiative)
- We illustrated risks inherent in specific clinical scenarios
- We described evidence which alters clinical choices for common practices
- We formulated improved care plans engaging interprofessional resources





Thank you!

Todd.James@ucsf.edu

Age-Friendly Health Systems 4M Training For Healthcare Practitioners

Questions?





South Florida Geriatric Workforce Enhancement Program

Age-Friendly Health Systems 4M Training For Healthcare Practitioners

Help us by completing an evaluation!

https://redcap.nova.edu/redcap/surveys/?s=CHETXK48Y4





Dr. Kiran C. Patel College of Osteopathic Medicine NOVA SOUTHEASTERN UNIVERSITY Florida

South Florida Geriatric Workforce Enhancement Program

Age-Friendly Health Systems 4M Training For Healthcare Practitioners Join us Next Week!

Module 1: Introduction to Age-Friendly Health Systems

• Thursday, June 3, 2021 • 10:00 am EST

Module 2: Deep Dives – What Matters Most & Mobility

• Thursday, June 10, 2021 • 10:00 am EST

Module 3: Deep Dives – Mentation & Medication

• Thursday, June 17, 2021 • 10:00 am EST



Module 4: Putting it All Together

• Thursday, June 24, 2021 • 10:00 am EST

Age-Friendly Health Systems 4M Training For Healthcare Practitioners

Thank you!

Contact Information for Today's Speakers:

- Isabel Rovira, Co-Founder/COO, Urban Health Partnerships: isabel@urbanhp.org
- Dr. Raymond Ownby, Professor and Chair, Department of Psychiatry and Behavioral Medicine, Nova Southeastern University <u>ro71@nova.edu</u>
- Dr. Todd James, Associate Professor of Medicine, USCF Division of Geriatrics: <u>Todd.James@ucsf.edu</u>



Dr. Kiran C. Patel College of Osteopathic Medicine NOVA SOUTHEASTERN UNIVERSITY Florida

South Florida Geriatric Workforce Enhancement Program